secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084282
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma secures up to $250M loan at 8.25%; $200M funded to refinance existing debt
--------------------------------------------------------------------------------

- Tranche A of $200M funded on Feb 26, used to refinance $125M existing term loan and fund working capital.
- Loan bears fixed 8.25% interest quarterly; principal repayments start Q1 2030 in four equal quarterly installments.
- Second tranche of $50M available upon election by June 30, 2027, subject to conditions.
- No financial covenants; collateral includes substantially all assets including intellectual property.
- Loan matures 5 years from closing; prepayment subject to exit fee of 1% and makewhole within first year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/0001193125-26-084282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/d59490d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer